Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A inact mut |
| Therapy | PLX2853 |
| Indication/Tumor Type | female reproductive organ cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A inact mut | female reproductive organ cancer | no benefit | PLX2853 | Phase II | Actionable | In a Phase IIa trial, PLX2853 treatment demonstrated safety but failed to meet predetermined criteria for efficacy in patients with advanced gynecologic cancers harboring a pathogenic ARID1A mutation, resulting in a partial response in 7.1% (1/14, 1 patient with endometrial carcinoma) and stable disease in 35.7% (5/14) of evaluable patients (PMID: 37797273; NCT04493619). | 37797273 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37797273) | Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. | Full reference... |